Miraculins Signs Agreements With Diagnostic Technologies, DTL, CIIRDF

Miraculins has finalized a research collaboration agreement with Diagnostic Technologies. The company has also announced the execution of a cooperation and project funding agreement with DTL and CIIRDF (Canada-Israel Industrial Research and Development Foundation).

Through the research project, the parties would collaborate to develop and test the performance of combinations of biomarkers for preeclampsia risk.

Miraculins has now completed the requisites for obtaining the first payment of $156,000, from its $467,000 share of the previously approved grant funding for a joint R&D project – marker and test platform to assess preeclampsia risk. The full grant is payable in three equal tranches over a two year period.

Christopher Moreau, President and CEO, Miraculins, said: We are very pleased with the support from the CIIRDF of our joint project and look forward to a productive relationship with the team from DTL.”

As our responsibilities under the project are largely aligned with our preeclampsia research program, we are pleased to be able to access additional non-dilutive capital to advance our lead research program. The potential commercialization of a product through our collaboration with DTL could help us to achieve increased access to global markets and help improve outcomes for expectant mothers and their children throughout the world.